Lexicon Pharmaceuticals LXRX Less than 12 months
Less than 12 months at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's less than 12 months.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's less than 12 months?
- Lexicon Pharmaceuticals (LXRX) reported less than 12 months of $123.1M in Q1 2026.
- How has Lexicon Pharmaceuticals's less than 12 months changed year-over-year?
- Lexicon Pharmaceuticals's less than 12 months increased by 114.8% year-over-year, from $57.3M to $123.1M.
- What is the long-term trend for Lexicon Pharmaceuticals's less than 12 months?
- Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's less than 12 months has grown at a -79.3% compound annual growth rate (CAGR), from $58.5M to $2.5M.